ProfileGDS5678 / 1451622_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 90% 90% 91% 89% 91% 92% 91% 91% 90% 90% 91% 90% 91% 91% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.1120490
GSM967853U87-EV human glioblastoma xenograft - Control 27.3359290
GSM967854U87-EV human glioblastoma xenograft - Control 37.3731991
GSM967855U87-EV human glioblastoma xenograft - Control 47.1866489
GSM967856U87-EV human glioblastoma xenograft - Control 57.4733691
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.4083692
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.2959891
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.3071391
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.1398490
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.2368390
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.2813591
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.2802490
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.402891
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.3615691